Study: CSII treatment boosts glucose control in type 1 diabetes

Continuous subcutaneous insulin infusion treatment was effective in lowering A1C levels in children with type 1 diabetes, with improvements sustained at 48 months, according to a study presented at the annual meeting of the Pediatric Academic Societies. CSII treatment lacks cost-effectiveness but is safe and well-tolerated compared with multiple daily injections, researchers said.

View Full Article in:

CSII therapy improved HbA1c in children with type 1 diabetes - Endocrine Today

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT